This is a preview of subscription content, log in via an institution to check access.
Notes
human epidermal growth factor receptor 2
Reference
Wang S-Y, et al. Incorporating Tumor Characteristics to Maximize 21-Gene Assay Utility: A Cost-Effectiveness Analysis. Journal of the National Comprehensive Cancer Network 17: 39-46, No. 1, Jan 2019. Available from: URL: http://dx.doi.org/10.6004/jnccn.2018.7077
Rights and permissions
About this article
Cite this article
Oncotype DX not cost effective in low-risk breast cancer. PharmacoEcon Outcomes News 823, 20 (2019). https://doi.org/10.1007/s40274-019-5710-3
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-019-5710-3